Overview

Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Insulin
Vildagliptin